Epidemiology/Antibiogram Report - How to Interpret
by
Raymond
B. Otero, Ph.D.
Consultant
220
Delmar Dr.
Richmond,
KY 40475
A. Introduction
Nursing homes
must be made more aware of problems that create infections, why do they occur
and how they can be reduced. OBRA has indicated that nursing homes have to
develop a surveillance system that answers the following questions:
1.
Can the surveillance system analyze clusters of infections?
2.
Can the surveillance system analyze changes in prevalent organisms?
3.
Can the surveillance system detect increases in the rate of infection in
a timely manner?
Since most nursing homes in this country
utilize reference laboratories to process their microbiological specimens, it is
important that these nursing homes request certain type of information that will
help them in answering the above questions. What I will be presenting to you in
the following pages are examples of what laboratories should provide you with in
a timely manner. If you have any questions concerning this information, please
contact me at my home office.
B. Table 1 - Specimen counts by source
category - current and year to date (YTD)
Table 1 gives you a monthly count of specimens
and a year-to-date or cumulative 12 month total of specimens. The purpose of
this table is to give you information on the number of specimens that cultured
significant isolates. This will give you information on the numbers and types of
specimens being submitted within your facility. You can actually plot the number
and types of specimens being submitted over a period of time to see changes in
frequencies. For example, if you find that the number of wound isolates are
increasing over time (6 months), this could be a good indicator of rising
infections in that anatomical location, or an increase in the number of cultures
due to better conscientious in culturing from infected sites. Table 1 shows the
results of a particular month of specimen counts and Figure 1 demonstrates how
this table can be graphed for surveillance purpose and education.
Table
1 - Specimen Counts
Significant
Isolates
Healthcare
USA – December 2000
|
|
Current |
|
YTD1 |
|
|
|
12-1-00 -12-31-00 |
|
01-01-00 - 12-31-00 |
|
|
Source |
Count |
Percent |
Count |
Percent |
|
Blood |
1 |
.02 |
6 |
1.7 |
|
Body fluids |
0 |
0 |
1 |
0.2 |
|
Respiratory |
4 |
7.2 |
22 |
6.2 |
|
Stool |
0 |
0 |
1 |
0.2 |
|
Urine |
29 |
52.7 |
223 |
62.9 |
|
Wound |
12 |
21.8 |
65 |
18.4 |
|
Other |
9 |
16.4 |
36 |
10.2 |
|
|
|
|
|
|
|
Total |
55 |
|
354 |
|
1Year-to-date
If you look at Table 1, you will notice that
urine specimen was the most common specimen submitted from this long term care
facility. In most nursing homes, urine specimens generally make up more than 50%
of the total number of specimens submitted. The year-to-date (YTD) also
demonstrates the same results. If wound specimens start outnumbering urine
specimens counts, this would indicate that a major problem was developing. A
quick check of this table and comparing it with other months will give the
facility an idea what is happening to the residents.

If you look at Figure 1, a simple graph can be
developed to show if there are beginning problems within your facility. For
example, upon examination of Figure 1, you will see that there is an increase in
wound isolates over a 6 month period. Perhaps a reexamination of the charts and
residents may be appropriate to see what is really going on. There are possibly
three reasons why this is occurring. First, there may be an increase awareness
of culturing areas which demonstrate infections (i.e., purulence), second there
are significant rises in wound infections, or third, surveillance cultures were
being performed to rule out a particular organism (i.e., MRSA).
C. Table 2 - Facility totals by organisms -
current and YTD
Table 2 tabulates the total number of isolates
for the current month and year-to-date. Table 2 provides you with a total number
(count) and percentage of the total number of isolates. For example, Table 2
shows that in December 2000, this facility had a total number of 75 isolates. Escherichia
coli was cultured 26 times for a percentage of 34.7 (26/75 x 100 = 34.7%).
The YTD (01-01-00 – 12-31-00) showed that E. coli was cultured 223
times for a percentage of 35% (223/637 x 100 = 35%). This table can be used to
compare the total number of isolates that were cultured in your facility over
months. For example, if the total number of isolates per month in your facility
averaged 45 over 2000, and now you are averaging 65 for the last half of 2000,
then you need to look at the remaining tables in the epidemiology report to see
what is going on.
Table
2 - Facility total by organisms
Healthcare
USA – December 2000
|
|
Current |
|
YTD |
|
|
|
12-01-00 - 12-31-00 |
|
01-01-00 - 12-31-00 |
|
|
Organism |
Count |
Percent |
Count |
Percent |
|
Enterococcus |
12 |
16 |
103 |
16.2 |
|
Enterobacter cloacae |
5 |
6.7 |
46 |
7.2 |
|
Escherichia coli |
26 |
34.7 |
223 |
35 |
|
Klebsiella pneumoniae |
7 |
9.3 |
59 |
9.3 |
|
MRSA |
9 |
12 |
63 |
9.9 |
|
Pseudomonas aeruginosa |
3 |
4 |
41 |
6.4 |
|
Proteus mirabilis |
9 |
12 |
81 |
12.7 |
|
Providencia rettgeri |
1 |
1.3 |
9 |
1.4 |
|
Staphylococcus aureus |
3 |
4 |
12 |
1.9 |
|
|
|
|
|
|
|
Total |
75 |
|
637 |
|
Graphs can also be produced from Table 2
(Figure 2). You may also want to graph a certain type of organism over a period
of time, e.g., MRSA isolates (Figure 3) to determine cluster or rises in
infections over time. Another example for the use of Table 2 is performing
surveillance on the incidence of potentially resistant organisms (Figure 4). As
you all know by now, there are increases of multi-resistant organisms in health
care and the Centers for Disease Control and Prevention (CDC) have issued an
alert on vancomycin-resistant Enterococcus faecalis. If you see these
isolates continually rising, the chances for obtaining a resistant form
increases. Pseudomonas aeruginosa, a gram negative rod often found in the
environment is now one of the major causes of infections in the compromising
host. This organism is intrinsically resistant to many antibiotics but we are
now seeing it develop resistance to aminoglycosides and other major antibiotics.
Table 2 can be used as a good surveillance tool to show you what is happening
over time.



D. Table
3 - Incidence of organisms within Source category - current and YTD
Table 3 provides you with information
concerning where the organisms listed in Table 2 are being isolated (source).
Since urine is a common specimen submitted for microbiological analysis, I will
use it as an example. There were a total of 54 isolates cultured from urine
(bottom figure under urine). Enterococcus was cultured 12 (number in
parenthesis) times, Escherichia coli 26 times, and etc. The number not in
parenthesis is the percent of the total number isolated from urine (i.e., Escherichia
coli = 26/54 x 100 = 48.1%). This means of the total isolates cultured in
urine, Escherichia coli made up 48.1% of the total number.
Table
3 - Incidence of Organisms within source category
Healthcare
USA
December
2000
|
Organism |
Blood |
Body fluids |
Respiratory |
Stool |
Urine |
Wound |
Other |
|
Enterococcus |
- |
- |
- |
- |
(12) 22.2 |
- |
(5) 16.1 |
|
Enterobacter cloacae |
- |
- |
(1)1 5.62 |
- |
(4) 7.4 |
(5) 17.9 |
(1) 3.2 |
|
E. coli |
- |
- |
(3) 16.7 |
- |
(26) 48.11 |
(11) 39 |
(8) 25.8 |
|
Klebsiella pneumoniae |
- |
- |
(5) 27.8 |
- |
(2) 3.7 |
(1) 3.6 |
(2) 6.5 |
|
MRSA |
(1) 100 |
- |
(6) 33.3 |
- |
(3) 5.6 |
(8) 28.6 |
(6) 19.4 |
|
Pseudomonas aeruginosa |
- |
- |
(3) 16.7 |
- |
(6) 11.1 |
(3) 10.7 |
(2) 6.5 |
|
Providencia rettgeri |
- |
- |
- |
- |
(1) 1.9 |
- |
(3) 9.6 |
|
Staphylococcus aureus |
- |
- |
- |
- |
- |
- |
(4) 12.9 |
|
|
|
|
|
|
|
|
|
|
Category total |
1 0.08 |
0 0.0 |
18 13.6 |
0 0.0 |
54 40.9 |
28 21.2 |
31 23.5 |
1Total number of isolates
2Percent of total within
source category (respiratory)
How important is Table 3? Very. For
example, since OBRA 1995 wants every nursing home to determine causes of
infection in order to reduce them, one can look for possible explanation of why
your residents are developing urinary tract infection. Examining Table 3, one
sees that 83.3% of all of the isolates in urine were from enteric sources (Enterococcus
12, Enterobacter cloacae 4, Escherichia coli 26, Klebsiella
pneumoniae 2, and Providencia rettgeri 1, make up 45/54 = 83.3%).
This should indicate to the person involved in staff development that more
emphasis must be placed on perianal cleansing of the residents. Graphic displays
of the data in Table 3 can accentuate findings (Figure 5). As Figure 5
indicates, there has been a continual rise in enteric isolates in all 4 quarters
for 2000. Figure 6 shows how surveillance can be performed using graphic tools.
As you can see by this figure a steady rise of MRSA isolates occurred in July,
August and September of 2000. However, through recognition and re-emphasizing
Standard Precautions, this facility was able to reduce the numbers.
Figure 7 shows how you can get fancy with graphics. Using MRSA isolates as an
example, one can determine organism vs. source and pinpoint a specific
anatomical region. These graphics really enhance presentations.



E. Table 4 - Distribution of Isolates by
Source Category - current and YTD
Table 4 tabulates the distribution of
isolates by source. For example, 70.6% of all Enterococcus isolated
within the facility came from urine specimens (17 Enterococcus were
isolated = 12/17 x 100 = 70.6%), 54.2% of all Escherichia coli isolates
(26/48 x 100 = 54.2%) were from urine. Table 4 gives you a quick look on
what source a particular organism was found. Again, if you find that the
majority of isolates from urines or wounds are enterics, the residents are
probably indigenously infecting themselves.
Note: The year-to-date tabulations that will
follow each current table can be interpreted in the same manner.
Table
4 - Distribution of Isolates by Source
Healthcare
USA
December
2000
|
Organisms |
Blood |
Body fluids |
Respiratory |
Stool |
Urine |
Wound |
Other |
Total |
|
Enterococcus |
- |
- |
- |
- |
(12) 70.6 |
- |
(5) 29.4 |
(17) 2.9 |
|
Enterobacter cloacae |
- |
- |
(1)1 9.12 |
- |
(4) 36.4 |
(5) 45.5 |
(1) 9.1 |
(11) 8.3 |
|
E. coli |
- |
- |
(3) 6.3 |
- |
(26) 54.2 |
(11) 22.9 |
(8) 16.7 |
(48) 36.4 |
|
Klebsiella pheumoniae |
- |
- |
(5) (50) |
- |
(2) 20 |
(1) 10 |
(2) 10 |
(10) 7.6 |
|
MRSA |
(1) 0.04 |
- |
(6) 25 |
- |
(3) 12.5 |
(8) 33.3 |
(6) 24 |
(24) 18.2 |
|
Pseudomonas aeruginosa |
- |
- |
(3) 21.4 |
- |
(6) 42.9 |
(3) 21.4 |
(2) 14.3 |
(14) 10.6 |
|
Providencia rettgeri |
- |
- |
- |
- |
(1) 25 |
- |
(3) 75 |
(4) 3.0 |
|
S. aureus |
- |
- |
- |
- |
- |
(4) 100 |
- |
(4) 3.0 |
1Total number of isolates
2Percent of total by source
F. Table
5 - Infection Control Detail by Organism - current or YTD
Table 5 needs to be kept confidential. This
table lists the patient’s name, ID number, organism isolated and source. This
table will also list the referring physician. The organisms will be listed
alphabetically. You can use this table to show what area of your facility is
submitting specimens that contain MRSA. Also, you can make evaluation of your
staff on perianal cleansing of your residents by looking for the enteric
isolates and the location of the residents. Perhaps this may cut down on group
participation in-service educational programs and go one-on-one in problem
areas. This is an excellent table to help infection control practitioners
determine location of problems within their facility.
Table
5 - Infection Control Detail by Organism
Healthcare
USA
December
2000
|
Organism/date |
Patient ID |
Location1 |
Patient name |
Referring MD |
Source2 |
|
Enterococcus 29 Dec 2000 |
|
E-13 |
Harley, John |
Jones, L. |
Urine |
|
Escherichia
coli 13 Dec 2000 |
|
E-10 |
Smith, Robert |
Jones, L. |
Urine (cath) |
|
MRSA 22 Dec 2000 |
|
A-12 |
Mardon, David |
Ross, E. |
Wound |
|
Proteus
mirabilis 18 Dec 2000 |
|
B-12 |
Snyder, Jim |
Jones, L. |
Urine |
1Make certain that staff members
place the location of the resident on the requisition form.
2Make certain that staff members place the anatomical location of the
source on the requisition form.
F. Table 6 - Infection Control Detail by
location - current and YTD
Table 6 also needs to be kept confidential
because of patient name listing. This table accomplishes what OBRA’s 1995
guidelines that each facility must be able to determine clusters of infections.
This table gives you a quick location of where organisms are being isolated. The
locations are placed on the first column in sequential order.
Table
6 - Infection Control Detail by Location
Healthcare
USA
December
2000
|
Location1/organism |
Date |
Patient name |
Patient ID |
Referring MD |
Source2 |
|
A-12 MRSA |
22 Dec 2000 |
Mardon, David |
|
Ross, E. |
Wound |
|
B-12 Proteus mirabilis |
18 Dec 2000 |
Snyder, Jim |
|
Jones, L. |
Urine |
|
E-10 Escherichia coli |
13 Dec 2000 |
Smith, Robert |
|
Jones, L. |
Urine (cath) |
|
E-13 Enterococcus |
29 Dec 2000 |
Harley, John |
|
Jones, L. |
Urine |
1Make certain that staff members place the location of the resident on
the requisition form.
2Make certain that staff members
place the anatomical location of the source on the requisition form.
G. Table 7 - Infection Control Detail by
Patient - current and YTD
This table should also be kept
confidential. Table 7 is just a rearrangement of data. The resident’s are
listed in alphabetical order for easy access. One good use of this table is to
show the facility which resident is constantly developing infections over time.
For example, prophylactic administration of antibiotics for reducing urinary
tract infections may indicate several types of organisms being isolated from a
particular patient over time. It is interesting to note that Licensure and
Regulation is looking for persistent infections among residents over time such
as urinary tract infections. This table can be shown to the infection
control/quality review committee.
Table
7 - Infection Control Detail by Patient
Healthcare
USA
December
2000
|
Name/organism |
Patient ID |
Date |
Location1 |
Referring MD |
Source2 |
|
Harley,
John Enterococcus |
|
29 Dec 2000 |
E-13 |
Jones, L. |
Urine |
|
Mardon,
Dave MRSA |
|
22 Dec 2000 |
A-12 |
Ross, E. |
Wound |
|
Smith, Robert Escherichia coli |
|
13 Dec 2000 |
E-10 |
Jones, L. |
Urine (cath) |
|
Snyder,
Jim Proteus mirabilis |
|
18 Dec 2000 |
B-12 |
Jones, L. |
Urine |
1Make certain that staff members
place the location of the resident on the requisition form.
2Make certain that staff members
place the anatomical location of the source on the requisition form.
H. Table
8 - Infection Control Detail by Source Category - current
The tables that follow Table 7 in the
epidemiology report are summation tables. For example Table 8 summarizes all the
urine isolates with organism, date of report, patient ID, location, patient
name, referring physician, and source. There are 7 of these tables and they
summarize all the isolates from blood, body fluids, respiratory, stools, urine,
wounds and others. The organisms are listed in the first column in alphabetical
order.
Table
8 - Infection Control Detail by Source
Healthcare
USA
Urine
|
Organism |
Date |
Patient ID |
Location |
Patient Name |
Referring MD |
Source |
|
Enterococcus |
8 Dec 2000 |
|
A-12 |
Smith, Arby |
Jones, L. |
Urine |
|
Enterococcus |
14 Dec 2000 |
|
E-22 |
Toast, Melba |
Jones, L. |
Urine |
|
Escherichia coli |
16 Dec 2000 |
|
C-8 |
Lucky, Tom |
Ross, E. |
Urine (cath) |
|
Klebsiella pneumoniae |
23 Dec 2000 |
|
A-4 |
Parker, Patricia |
Shula, D. |
Urine |
|
MRSA |
6 Dec 2000 |
|
E-12 |
Clinton, William |
Ross, E. |
Urine |
|
Proteus mirabilis |
14 Dec 2000 |
|
B-3 |
Dole, Elliot |
Jones, L. |
Urine (cath) |
It is imperative that the facility fills out the requisition form in the following manner:
1. Patient’s name*
2. Date of obtainment of specimen
3. Time of obtainment of specimen
4. Specific site, i.e., right ankle (left
side) decubitus*
5. Patient ID number from facility for
identification for surveillance
6. Referring physician*
7. Specific location of resident (for
facility surveillance)*
*These are important demographics so that
your epi reports are complete.
Table 8 above can be used to determine
specific type organism being isolated over time within the facility. For
example, if I wanted to determine the number of isolates of MRSA from specific
residents over time, I would get a summary report (6 months or 12 months) from
the reference laboratory and plot them on a graph. See Figure 8 to show you what
I mean.

As you can see, there were many isolates
obtained during the last 6 months of 2000, however, you will also notice that
fewer residents were involved. If you also separate the colonized from the
infected (see Figure 7), the numbers would also in all probability be less. The
number of isolates of MRSA is not as important as to the explanation of its
occurrence.
I feel that these tables and figures given
above will accomplish OBRA’s 1995 goals. If you have any questions, please do
not hesitate in calling me at my home office (859-623-3973). My e-mail address
is: belinotero@aol.com.
My web site is: http://www.cinetwork.com/otero.
Infection Control is an exciting field. It
can be performed by facilities at a reasonable cost. With monitory fines coming
up, each facility must be prepared to defend their system. Let me help you.
Antibiogram Report
A. Introduction
The antibiogram report accompanies the
epidemiology report. This report is important for the Infection Control
Practitioner (ICP), Physician, Pharmacists and the Nurses on the floors. The
antibiogram report contains the following information:
Organisms
isolated
Source
(blood, urine, wound)
Number of
isolates (ISO)
List of
antibiotics tested*
Percent
susceptible (100%, 75%, 67%, etc.)
B. Codes (abbreviations)
Table 10 will interpret the codes for the
antibiotics:
Table 10 - Code
Identification
|
Code |
Antibiotic |
|
AN |
Amikacin |
|
AMC |
Amoxicillin/clavulanic acid |
|
AMS |
Ampicillin/subbactam |
|
AM |
Ampicillin |
|
AZT |
Aztreonam |
|
CB |
Carbenicillin |
|
CZ |
Cefazolin |
|
CCL |
Cefaclor |
|
CID |
Cefonicid |
|
FOX |
Cefoxitin |
|
TAZ |
Ceftazidime |
|
CTR |
Ceftriaxone |
|
ROX |
Cefuroxime |
|
CF |
Cephalothin |
|
C |
Chloramphenicol |
|
CIP |
Ciprofloxin |
|
CC |
Clindmycin |
|
E |
Erythromycin |
|
GM |
Gentamycin |
|
IMI |
Imipenem |
|
|